Drugs / 99mTc-MAG3-BIIB067
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03764488 | Dec 2018 → Jun 2021 | — | Biogen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-MAG3-BIIB067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03764488 ↗ |
| Route | Intrathecal | “Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).” NCT03764488 ↗ |